Kilton L J, Benson A B, Greenberg A, Johnson P, Shapiro C, Blough R, French S, Weidner L
Northwestern University, Chicago, Illinois.
Invest New Drugs. 1992 Aug;10(3):201-4. doi: 10.1007/BF00877246.
We have conducted a phase II trial of fludarabine phosphate for advanced measurable adenocarcinoma of the pancreas. The drug was administered every 4 weeks by a daily-times-5 bolus schedule beginning at 20 mg/m2/day. No responses were observed in 20 evaluable patients, 18 of whom were previously untreated. Dose-limiting toxicity was leukopenia, and gastroenterologic side effects were frequent. Life-threatening or fatal renal dysfunction occurred in 3 patients. In this schedule fludarabine phosphate is ineffective against adenocarcinoma of the pancreas and appears to have unpredictable severe renal toxicity.
我们开展了一项关于磷酸氟达拉滨治疗晚期可测量胰腺腺癌的II期试验。药物通过每日5次推注方案，每4周给药一次，起始剂量为20mg/m²/天。20例可评估患者中未观察到缓解，其中18例此前未接受过治疗。剂量限制性毒性为白细胞减少，胃肠道副作用常见。3例患者出现危及生命或致命的肾功能不全。在此给药方案下，磷酸氟达拉滨对胰腺腺癌无效，且似乎具有不可预测的严重肾毒性。
